Page last updated: 2024-11-08

cyclo(tyrosyl-tyrosyl)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyclo(tyrosyl-tyrosyl): structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cyclo(tyrosyl-tyrosyl) : A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by p-hydroxybenzyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

cyclo(L-tyrosyl-L-tyrosyl) : A cyclo(tyrosyl-tyrosyl) in which both stereocentres have L-configuration. Synthesized by Mycobacterium tuberculosis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID192816
CHEMBL ID2002640
CHEBI ID65048
SCHEMBL ID1225724
MeSH IDM0230097
PubMed CID11267350
CHEMBL ID189558
CHEBI ID65063
SCHEMBL ID13399579
MeSH IDM0230097

Synonyms (53)

Synonym
3,6-bis(4-hydroxybenzyl)-2,5-piperazinedione
3,6-bis[(4-hydroxyphenyl)methyl]piperazine-2,5-dione
NCI60_031337
nsc-686960
nsc686960
3,6-bis(4-hydroxybenzyl)piperazine-2,5-dione
5625-40-1
CHEBI:65048 ,
3,6-bis[(4-hydroxyphenyl)methyl]-2,5-piperazinedione
cyclodityrosine
3,6-di(4-hydroxybenzyl)-2,5-dioxopiperazine
dicyclotyrosine
cyclo(tyrosyl-tyrosyl)
2,5-piperazinedione, 3,6-bis((4-hydroxyphenyl)methyl)-
cyclo(tyr-tyr)
3,6-bis(4-hydroxybenzyl)piperazine-2,5-quinone
AKOS025243801
SCHEMBL1225724
CHEMBL2002640
AS-66867
Q27104926
3,6-bis[(4-hydroxyphenyl)methyl]-3,6-dihydropyrazine-2,5-diol
DTXSID90971679
PD036421
cyy ,
cyclo(l-tyr-l-tyr)
ytt ,
(3s,6s)-3,6-bis(4-hydroxybenzyl)piperazine-2,5-dione
DB08761
CHEMBL189558 ,
chebi:65063 ,
2,5-piperazinedione, 3,6-bis[(4-hydroxyphenyl)methyl]-, (3s,6s)-
C20516
cyclo-(l-tyr)2
cyclo(l-tyrosyl-l-tyrosyl)
cyclo(l-tyrosyl-l-tyrosine)
cyclodi-l-tyrosine
(3s)-cis-3,6-bis-(4-hydroxy-benzyl)-piperazine-2,5-dione
10125-11-8
cyclo-(l-tyrosyl-l-tyrosine)
cyclo-(l-tyr-l-tyr)
SCHEMBL13399579
cyclo-(l-tyrosyl-l-tyrosyl)
bdbm50505734
'cyclo(tyrosyl-tyrosyl); cyclo(tyr-tyr)'
cyclo(tyrosyltyrosyl)
Q27097946
(3s,6s)-3,6-bis[(4-hydroxyphenyl)methyl]piperazine-2,5-dione
A905295
(3s,6s)-3-[(4-hydroxyphenyl)methyl]-6-(1h-indol-3-ylmethyl)-2,5-piperazinedione
DTXSID001310862
PD004555
EN300-37402812
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2,5-diketopiperazinesAny piperazinone that has a piperazine-2,5-dione skeleton.
cyclo(tyrosyl-tyrosyl)A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by p-hydroxybenzyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
mycocyclosin biosynthesis25

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 Mycobacterium tuberculosisKd30.00002.40002.40002.4000AID1526909
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1639191Binding affinity to Mycobacterium tuberculosis H37Rv CYP121A1 by UV-visible scanning spectrophotometric analysis2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1.
AID1526912Binding affinity to Mycobacterium tuberculosis Mycobacterium tuberculosis CYP121 expressed in Escherichia coli HMS174 (DE3) assessed as compound-adduct formation by measuring high spin complex by UV-visible scanning spectrophotometric analysis relative to2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1543349Growth inhibition of Staphylococcus aureus ATCC 6538 incubated for 24 hrs under aerobic condition by microdilution method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543336Antibiofilm activity against Porphyromonas gingivalis ATCC 33277 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1866106Binding affinity to Mycobacterium tuberculosis CYP121A1 expressed in Escherichia coli HMS174 (DE3) assessed as dissociation constant by competitive UV-visible spectroscopic analysis2022European journal of medicinal chemistry, Feb-15, Volume: 230A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen).
AID1478060Binding affinity to Mycobacterium tuberculosis CYP121A1 expressed in Escherichia coli TG1 (DE3) by UV-visible scanning spectrophotometric analysis
AID1526914Binding affinity to Mycobacterium tuberculosis CYP121 expressed in Escherichia coli HMS174 (DE3) assessed as compound-adduct formation by measuring high spin complex at 0.5 to 2 mM incubated for 20 mins by EPR Spectroscopic method (Rvb = 0%)2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of
AID1543346Antiadherence activity against FITC-labelled Candida albicans ATCC 28366 assessed as reduction in bacterial adhesion to hydroxylapatite up to 96 ug/mL after 1 hr by fluorescence assay relative to control2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID243894Percent inhibition of human calpain 1 at 500 uM; Inhibition within 110%2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis of a small library of diketopiperazines as potential inhibitors of calpain.
AID1543334Displacement of [3H]DAMGO from mu-opioid receptor in Long-Evans rat brain after 1 hr by liquid scintillation counting method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1852781Binding affinity to recombinant Mycobacterium tuberculosis CYP121A1 assessed as soret band shift and measured after 15 mins by UV-visible spectroscopic analysis (Rvb= 417 nm)2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Synthesis, biological evaluation and computational studies of pyrazole derivatives as
AID1543339Bactericidal activity against Streptococcus mutans ATCC 251752019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543360Antibiofilm activity against Actinomyces naeslundii ATCC 49340 assessed as reduction in biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining-based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543362Growth inhibition of Candida albicans ATCC 28366 up to 96 ug/ml measured after 24 hrs by microdilution method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543354Antibiofilm activity against Streptococcus mutans ATCC 25175 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining-based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543348Growth inhibition of Listeria monocytogenes WSLC 1001 incubated for 24 hrs under aerobic condition by microdilution method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543351Growth inhibition of Escherichia coli ATCC 15939 incubated for 24 hrs under aerobic condition by microdilution method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543342Antibiofilm activity against Lactobacillus fermentum LacB1 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543350Growth inhibition of Pseudomonas aeruginosa ATCC 10145 incubated for 24 hrs under aerobic condition by microdilution method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1852780Binding affinity to recombinant Mycobacterium tuberculosis CYP121A1 assessed as dissociation constant and measured after 15 mins by UV-visible spectroscopic analysis2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Synthesis, biological evaluation and computational studies of pyrazole derivatives as
AID1543338Growth inhibition of Streptococcus mutans ATCC 25175 incubated for 24 hrs under aerobic condition by microdilution method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1526909Binding affinity to Mycobacterium tuberculosis CYP121 expressed in Escherichia coli HMS174 (DE3) by UV-visible scanning spectrophotometric analysis2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of
AID1543335Antibiofilm activity against Fusobacterium nucleatum ATCC 25586 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543347Antiadherence activity in FITC-labelled Streptococcus mutans ATCC 25175 assessed as reduction in bacterial adhesion to hydroxylapatite up to 96 ug/mL after 1 hr fluorescence assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543357Antibiofilm activity against Candida albicans ATCC 28366 assessed as reduction of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1543364Inhibition of planktonic growth of Streptococcus mutans ATCC 25175 up to 96 ug/mL after 24 hrs relative to control2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (6.67)18.2507
2000's2 (13.33)29.6817
2010's8 (53.33)24.3611
2020's4 (26.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]